Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab Plus Lenalidomide in Relapsed or Refractory DLBCL
NCT05429268Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Dec 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Started Dec 2022; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05429268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429268.